Tal1 transgenic expression reveals absence of B lymphocytes

Cancer Research

Volumn 66, Issue 12, 2006, Pages 6014-6017

  Palamarchuk, Alexey ^a   Zanesi, Nicola ^a   Aqeilan, Rami I ^a   Efanov, Alexey ^a   Maximov, Vadim ^a   Santanam, Urmila ^a   Hagan, John P ^a   Croce, Carlo M ^a   Pekarsky, Yuri ^a,b  

^a THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; CD 43 ANTIGEN; CD19 ANTIGEN; CD45 ANTIGEN; IMMUNOGLOBULIN M; PROTEIN TAL1; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; B LYMPHOCYTE; BONE MARROW CELL; CONTROLLED STUDY; FLUORESCENCE ACTIVATED CELL SORTING; GENE; GENE EXPRESSION; IGH GENE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TRANSGENICS;

ANIMALS; B-LYMPHOCYTES; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; HUMANS; IMMUNOGLOBULIN HEAVY CHAINS; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; PROMOTER REGIONS (GENETICS); PROTO-ONCOGENE PROTEINS;

EID: 33745700225     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-06-0937     Document Type: Article

References (12)

1. Begley CG, Green AR. The SCL gene: from case report to critical hematopoietic regulator. Blood 1999;93:2760-70.
2. O'Neil J, Billa M, Oikemus S, Kelliher M. The DNA binding activity of TAL-1 is not required to induce leukemia/lymphoma in mice. Oncogene 2001;20:3897-905.
3. O'Neil J, Shank J, Cusson N, Murre C, Kelliher M. TAL1/SCL induces leukemia by inhibiting the transcriptional activity of E47/HEB. Cancer Cell 2004;5:587-96.
4. Mikkers H, Allen J, Berns A. Proviral activation of the tumor suppressor E2a contributes to T cell lymphomagenesis in EμMyc transgenic mice. Oncogene 2002;21:6559-66.
5. Porcher C, Swat W, Rockwell K, Fujiwara Y, Alt FW, Orkin SH. The T cell leukemia oncoprotein SCL/tal-1 is essential for development of all hematopoietic lineages. Cell 1996;86:47-57.
6. Bain G, Maandag EC, Izon DJ, et al. E2A proteins are required for proper B cell development and initiation of immunoglobulin gene rearrangements. Cell 1994;79:885-92.
7. Herblot S, Aplan PD, Hoang T. Gradient of E2A activity in B-cell development. Mol Cell Biol 2002;22:886-900.
8. Goardon N, Schuh A, Hajar I, et al. Ectopic expression of TAL-1 protein in Ly-6E.1-htal-1 transgenic mice induces defects in B- and T-lymphoid differentiation. Blood 2002;100:491-500.
9. Palamarchuk A, Efanov A, Maximov V, Aqeilan RI, Croce CM, Pekarsky Y. Akt phosphorylates Tal1 oncoprotein and inhibits its repressor activity. Cancer Res 2005;65:4515-9.
10. Shaw AC, Swat W, Ferrini R, Davidson L, Alt FW. Activated Ras signals developmental progression of recombinase-activating gene (RAG)-deficient pro-B lymphocytes. J Exp Med 1999;189:123-9.
11. Pekarsky Y, Hallas C, Palamarchuk A, et al. Akt phosphorylates and regulates the orphan nuclear receptor Nur77. Proc Natl Acad Sci U S A 2001;98:3690-4.
12. Bichi R, Shinton SA, Martin ES, et al. Human chronic lymphocytic leukemia modeled in mouse by targeted TCL1 expression. Proc Natl Acad Sci U S A 2002;99:6955-60.